Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder

J Affect Disord. 2010 Nov;126(3):430-5. doi: 10.1016/j.jad.2010.07.006. Epub 2010 Aug 1.

Abstract

Backgrounds: To determine the association between the brain derived neurotrophic factor (BDNF) Val66Met polymorphism and short-term antidepressant response in Taiwanese patients with major depressive disorder (MDD).

Methods: We recruited 117 MDD patients who were randomized to fluoxetine or venlafaxine treatment and 106 controls. The association between genotypes and percentage changes in the Hamilton Rating Scale for Depression (HAM-D) scores over time was analyzed by repeated-measures ANOVA. The antidepressants were included in the model as covariates.

Results: The frequency of the BDNF Val66Met polymorphisms was not significantly different between patient and control groups. Significantly changes in HAM-D scores were noted after 2 and 4 weeks of venlafaxine treatment among different genotypes.

Conclusions: Results suggest antidepressants acting through different mechanisms may affect the BDNF Val66Met polymorphism differently.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alleles*
  • Antidepressive Agents, Second-Generation / therapeutic use*
  • Cyclohexanols / therapeutic use*
  • Depressive Disorder, Major / drug therapy*
  • Depressive Disorder, Major / genetics*
  • Depressive Disorder, Major / psychology
  • Female
  • Fluoxetine / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Pharmacogenetics
  • Polymorphism, Single Nucleotide / genetics*
  • Taiwan
  • Venlafaxine Hydrochloride

Substances

  • Antidepressive Agents, Second-Generation
  • Cyclohexanols
  • Fluoxetine
  • Venlafaxine Hydrochloride